Registry for CRP apheresis after acute myocardial infarction

Registry for CRP apheresis after acute myocardial infarction - CAMI-Registry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017481

Enrollment

300

Registered

2019-06-28

Start date

2019-06-25

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I21

Interventions

Group 1: Patients with elevated CRP levels following guideline-based primary treatment of acute myocardial infarction may be treated with the CRP apheresis as a new treatment option for the targeted

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Acute myocardial infarction after guideline primary treatment, elevated CRP concentration

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Occurrence of cardiac events 30 days and 12 months after acute myocardial infarction	—

Secondary

Measure	Time frame
Heart pumping capacity (left ventricular ejection fraction, LVEF), Myocardial tissue damage in neuroimaging procedures, occurrence of undesirable effects of CRP apheresis.	—

Countries

Germany

Contacts

Public ContactBurghard Thiesen

Pentracor GmbH

info@pentracor.de+49 (0)3302 209 449-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026